The global Hutchinson Gilford Progeria Syndrome Market is expected to generate a market value of US$ 103.07 billion in 2023 and a market value of US$ 233.05 billion by 2023-2033, at a CAGR of 8.5%. The increasing population of the world, which contributes to more cases of the illness, is driving the growth of the Hutchinson Gilford progeria syndrome market.
The market for Hutchinson Gilford progeria syndrome grew at a 5.5% CAGR from 2017 to 2022.. Around 400 children worldwide are progeroid-affected at any given time, according to the National Organization for Rare Disorders (NORD), which estimates that Hutchinson Gilford progeria syndrome affects one in every 20 million people.
In the coming years, it is anticipated that the market for Hutchinson Gilford progeria syndrome treatments will grow quickly. The market for treatments for Hutchinson-Gilford Progeria Syndrome (HGPS) is likely to be primarily driven by the introduction of novel therapies and an increase in HGPS cases. The affected patients have a maximum life expectancy of 30 years, with an average life expectancy of 13 years. Almost 90% of patients die as a result of complications related to atherosclerosis.
Request Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16382
There was only one FDA-approved drug for the treatment of progeria until 2020. The other available treatment options were mostly aimed at reducing cardiovascular symptoms and growth abnormalities. Major institutes’ research and development activities to find novel therapies for age-related conditions are expected to provide lucrative opportunities for global market players.
Key Takeaways from the Market Study
- Hutchinson Gilford progeria syndrome market is expected to grow at a value of 8.5% CAGR for the forecast period 2023-2033
- Hospitals & surgical centres are expected to hold 50% market share for Hutchinson Gilford progeria syndrome market in 2023.
- North America is expected to possess 45% market share for Hutchinson Gilford progeria syndrome market in 2023.
- Asia Pacific Hutchinson Gilford progeria syndrome market size is expected to possess 40% market share in 2023.
“Increasing population across the globe along with investment by key players in therapeutics treatments and medication is creating lucrative opportunities for Hutchinson Gilford progeria syndrome market” states an FMI analyst
Speak to our Research Expert: https://www.futuremarketinsights.com/ask-question/rep-gb-16382
Competitive Landscape
Key players in the Hutchinson-Gilford progeria syndrome market Eiger BioPharmaceuticals, Teva Pharmaceutical, Inc., Amgen, Sanofi, Novartis AG, Schering-Plough, PRG Science & Technology Co., Ltd, Micro Interventional Devices Inc, Boston Scientific Corporation, CryoLife Inc.
- Micro Interventional Devices Inc, a key player in the Hutchinson Gilford progeria syndrome market is focusing on investing in research and development for innovating medications for treating Hutchinson-Gilford progeria syndrome.
- Boston Scientific Corporation, another key player in the Hutchinson Gilford progeria syndrome market has undertaken extensive research to innovate medication and treatment to increase the life cycle of patients suffering from Hutchinson Gilford progeria syndrome.
Key Segments Profiled in the Hutchinson-Gilford Progeria Syndrome Market Survey
Treatment:
- Farnesyltransferase Inhibitor (FTI)
- MRI scan
- Hearing tests
- Cardiovascular
- Others
End User:
- Hospitals & Surgical Centres
- Specialty Clinics
- Others
Visit for Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-16382
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Have a Look at Healthcare Domain Related Research Reports:
- https://cigarbook.mn.co/posts/31395498
- https://adhipatialumni.com/blogs/66102/Diamond-Blackfan-Anemia-DBAAAS-Syndrome-Therapeutics-Market-Future-Scenario-by
- https://writeablog.net/dzwgsrkjh6
- https://whotrades.com/go/3/43987103148?feedContext=limex
- https://www.rolonet.com/blogs/232310/Diamond-Blackfan-Anemia-DBAAAS-Syndrome-Therapeutics-Market-Future-Scenario-by
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs